NASDAQ:TNDM Tandem Diabetes Care Q3 2026 Earnings Date & Estimates $16.11 +0.43 (+2.74%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$15.86 -0.25 (-1.55%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Tandem Diabetes Care is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Tandem Diabetes Care in Q3 2026Tandem Diabetes Care is expected to post earnings of -$0.2451 per share on revenue of $265.86 million. In the same quarter a year earlier Tandem Diabetes Care reported -$0.31 per share on revenue of $249.25 million. Tandem Diabetes Care last reported on August 6, 2026, posting -$0.31 per share and beating the -$0.3207 consensus estimate. Tandem Diabetes Care has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.2451Expected Revenue$265.86 millionPrior-Year EPS-$0.31Prior-Year Revenue$249.25 millionExpected Revenue Growth+6.7%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.31 (Beat by +$0.0107)Last Quarter Revenue$254.56 millionEPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Tandem Diabetes Care Q3 2026 Earnings FAQ When does Tandem Diabetes Care report Q3 2026 earnings? Tandem Diabetes Care (NASDAQ:TNDM) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. What time is Tandem Diabetes Care's Q3 2026 earnings call? Tandem Diabetes Care's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Tandem Diabetes Care? Analysts expect Tandem Diabetes Care to post earnings of -$0.2451 per share for Q3 2026. How much revenue is Tandem Diabetes Care expected to report? The consensus revenue estimate for Tandem Diabetes Care is $265.86 million for Q3 2026. Tandem Diabetes Care Earnings HeadlinesTandem Diabetes Care (NASDAQ:TNDM) Stock Rating Upgraded by BarclaysOctober 8 at 6:06 AM | americanbankingnews.comBarclays initiates coverage of Tandem Diabetes Care at equal-weightOctober 7 at 1:36 PM | msn.comAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly 80% afterward. He also called the housing crisis and the collapse of Bear Stearns and Lehman Brothers before they happened. Now Tilson says the day after this year's midterm elections, America enters a period of economic change unlike anything seen in decades - and most investors are unprepared. | Stansberry Research (Ad)Tandem Diabetes Care (TNDM) Receives a Buy from RBC CapitalOctober 5, 2026 | theglobeandmail.comCitigroup Has Lowered Expectations for Tandem Diabetes Care (NASDAQ:TNDM) Stock PriceOctober 2, 2026 | americanbankingnews.comTandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026October 1, 2026 | finance.yahoo.comSee More Tandem Diabetes Care Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tandem Diabetes Care? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tandem Diabetes Care and other key companies, straight to your email. Email Address About Tandem Diabetes CareTandem Diabetes Care (NASDAQ:TNDM) is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to work with continuous glucose monitoring (CGM) systems and digital health tools to help automate and personalize insulin therapy. Tandem’s product portfolio includes the t:slim X2 insulin pump, which features a rechargeable design and software that supports automated insulin delivery. The company also offers the t:slim X2 pump with Control-IQ technology, an algorithm designed to adjust insulin delivery based on CGM readings, and the compact Tandem Mobi pump. Its t:connect diabetes management platform supports data collection, remote monitoring and therapy management for patients and healthcare providers. Founded in 2006 and headquartered in San Diego, California, Tandem Diabetes Care serves customers in the United States and international markets through direct commercial operations and distribution partners. The company’s products are intended for use by people with insulin-dependent diabetes, including individuals with type 1 diabetes. John Sheridan serves as the company’s president and chief executive officer.View Tandem Diabetes Care ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
